Neurocrine Biosciences Inc.

News & Events

Press Releases

In The Media

1. Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

   PR Newswire JUL 15, 2025 9:00 AM EDT
   Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare...
   READ ARTICLE

2. Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

   PR Newswire JUL 15, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients wit...
   READ ARTICLE

3. Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst(TM) Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting

   PR Newswire JUL 14, 2025 4:35 PM EDT
   Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Imp...
   READ ARTICLE

4. Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

   PR Newswire JUL 14, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (cri...
   READ ARTICLE

5. Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

   PR Newswire JUL 9, 2025 4:01 PM EDT
   Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Res...
   READ ARTICLE

6. Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

   PR Newswire JUN 30, 2025 4:05 PM EDT
   Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Lo...
   READ ARTICLE

7. Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

   PR Newswire JUN 27, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrati...
   READ ARTICLE

8. Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

   PR Newswire JUN 20, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Hea...
   READ ARTICLE

9. Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

   PR Newswire JUN 9, 2025 4:05 PM EDT
   Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer PR Newswire ...
   READ ARTICLE

10. Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO(TM) Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

    PR Newswire JUN 2, 2025 8:30 AM EDT
    Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstra...
    READ ARTICLE